Clinical

A5175 -A Phase IV, Prospective, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily Protease Inhibitor- And Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations For Initial Treatment Of HIV-1 Infected Individuals From Resource-Limited Settings (PEARLS) Trial

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

ACTG /NIH

FUNDING

ACTG/NIAID/NIH

KEY OBJECTIVE

DURATIONS

2005 - 2010

PUBLICATIONS

  1. Firnhaber C, Smeaton L, Saukila N et al. Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. Int J Infect Dis. 2010 Dec;14(12):e1088-92. PMID: 20961784
  2. Grinsztejn B, Smeaton L, Barnett R et al; the PEARLS study team of the ACTG.
  3. Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir Ther. 2011;16(7):1057-62. PMID: 22024521
  4. Safren SA, Hendriksen ES, Smeaton L et al. Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world.
  5. AIDS Behav. 2012 Feb;16(2):266-77. PMID: 21499794
  6. Campbell TB, Smeaton LM, Kumarasamy N et al; PEARLS Study team of the ACTG.  Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.
  7. PLoS Med. 2012;9(8):e1001290.
  8. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational seetings.  PMID: 22936892
  9. Périssé AR, Smeaton L, Chen Y et al; P E A R L S study team of the ACTG. Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease. PLoS One. 2013 Dec 31;8(12):e83643. PMID: 24391801
  10. Havers F, Smeaton L, Gupte N et al; ACTG PEARLS and NWCS 319 Study Teams. 25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings. J Infect Dis. 2014 Jul 15;210(2):244-53. PMID: 24799602
  11. Safren SA, Biello KB, Smeaton L et al; PEARLS (ACTG A5175) Study Team. Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS One. 2014 Aug 25;9(8):e104178. PMID: 25153084
  12. Touzard Romo F, Smeaton LM, Campbell TB et al. Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). HIV Clin Trials. 2014 Nov-Dec;15(6):246-60. PMID: 25433664
  13. Kantor R, Smeaton L, Vardhanabhuti S et al; on behalf of the A5175 Study Team. Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial. Clin Infect Dis. 2015 May 15;60(10):1541-9. PMID: 25681380
  14. Tenforde MW, Gupte N, Dowdy DW et al; ACTG PEARLS and NWCS 319 Study Group. C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings. PLoS One. 2015 Feb 26;10(2):e0117424. PMID: 25719208
  15. Firnhaber C, Smeaton LM, Grinsztejn B et al. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials. 2015 May-Jun;16(3):89-99. PMID: 25979186
  16. Balagopal A, Asmuth DM, Yang WT et al; ACTG PEARLS and NWCS 319 Study team. Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study. J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):163-71.
  17. Pre-cART Elevation of CRP and CD4+ T-cell Immune Activation Associated with HIV Clinical Progression in a Multinational Case-Cohort Study. PMID: 26017661
  18. Erlandson KM, Taejaroenkul S, Smeaton L et al. A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings. Open Forum Infect Dis. 2015 Jun 24;2(3):ofv095. PMID: 26213694
  19. Castillo-Mancilla JR, Aquilante CL, Wempe MF et al. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). J Antimicrob Chemother. 2016 Jun;71(6):1609-18. PMID: 26892777
  20. Mave V, Erlandson KM, Gupte N et al; ACTG PEARLS and NWCS 319 Study team. Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults. J Infect Dis. 2016 Jul 1;214(1):65-72. PMID: 26962236

A5199 -International Neurological Study- A Stand Alone Study for Participants of A5175 (A Phase IV, Randomized, Open-Label Evaluation of the Efficacy of Once Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Individuals from Diverse Areas of the World)

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

ACTG /NIH

FUNDING

ACTG/NIAID/NIH

KEY OBJECTIVE

DURATIONS

2005 - 2010

PUBLICATIONS

A5185 -Effect of Antiretroviral treatment of Genital Compartment virus in individuals initiating Potent Antiretroviral therapy from Resource limited settings.

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

ACTG /NIH

FUNDING

ACTG/NIAID/NIH

KEY OBJECTIVE

DURATIONS

2005 - 2010

PUBLICATIONS

Fiscus SA, Cu-Uvin S, Eshete AT et al; the A5185s Team. Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy. Clin Infect Dis. 2013 Jul;57(2):290-7. PMID: 23532477

A5207- Maintaining Options for Mothers Study (MOMS) – A Phase II Randomized Comparison of three Antiretroviral Strategies administered for 7 or 21 days to reduce the emergence of Nevirapine resistant HIV-1 following a single Intrapartum dose of Nevirapine

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

ACTG /NIH

FUNDING

ACTG/NIAID/NIH

KEY OBJECTIVE

DURATIONS

2007 - 2011

PUBLICATIONS

Saran Vardhanabhuti; Edward P. Acosta; Heather J. Ribaudo et al; the A5207 Study Team. Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission. J Infect Dis. 2013 Aug 15;208(4):662-71. PMID: 23687222

A5190- Assessment of Safety and Toxicity among Infants Born To HIV-1-Infected Women Enrolled in Antiretroviral Treatment Protocols in Diverse Areas of the World – A Limited Center Trial of the Adult AIDS Clinical Trials Group (AACTG) and the Pediatric AIDS Clinical Trials Group (PACTG), Conducted in Collaboration with the HIV Prevention Trials Network (HPTN)

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

ACTG /NIH

FUNDING

ACTG/NIAID/NIH

KEY OBJECTIVE

DURATIONS

2007 - 2011

PUBLICATIONS

Nielsen-Saines K, Komarow L, Cu-Uvin S et al; ACTG 5190/PACTG 1054 Study Team.  Infant outcomes after maternal antiretroviral exposure in resource-limited settings. Pediatrics. 2012 Jun;129(6):e1525-32. PMID: 22585772

A5221-STRIDE -A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis with CD4 < 250 Cells/mm3

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

ACTG /NIH

FUNDING

ACTG/NIAID/NIH

KEY OBJECTIVE

DURATIONS

2008 - 2010

PUBLICATIONS

Havlir DV, Kendall MA, Ive P et al; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20;365(16):1482-91. PMID: 22010914

A5230- A Pilot Study of Lopinavir/Ritonavir in Participants Experiencing Virologic Relapse on NNRTI-Containing Regimens

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

ACTG /NIH

FUNDING

ACTG/NIAID/NIH

KEY OBJECTIVE

DURATIONS

2010 - 2012

PUBLICATIONS

A5271- “Collection of Comparison Neurocognitive Data in Resource-Limited Settings”

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

ACTG /NIH

FUNDING

ACTG/NIMH/NIAID/NIH

KEY OBJECTIVE

DURATIONS

2012 - 2013

PUBLICATIONS

Robertson K, Jiang H, Evans SR et al; AIDS Clinical Trials Group. International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271. J Neurovirol. 2016 Aug;22(4):472-8. PMID: 26733457

A5265/GIVEN, “A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Gentian Violet Oral Solution to that of Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-1 Infected Participants in Non-U.S. Settings

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

ACTG /NIH

FUNDING

ACTG/NIAID/NIH

KEY OBJECTIVE

DURATIONS

2012

PUBLICATIONS

available separate file

A5273: Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT), A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

ACTG /NIH

FUNDING

ACTG/NIAID/NIH

KEY OBJECTIVE

DURATIONS

2012 - 2014

PUBLICATIONS

available separate file

A5274/REMEMBER- Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens A Site-Limited Trial of the AIDS Clinical Trials Group (ACTG)

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

ACTG /NIH

FUNDING

ACTG/NIAID/NIH

KEY OBJECTIVE

DURATIONS

2011 - 2014

PUBLICATIONS

Hosseinipour MC, Bisson GP, Miyahara S et; Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet. 2016 Mar 19;387(10024):1198-209. PMID: 27025337

HPTN 052-A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 In Serodiscordant Couples

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

HPTN/NIH

FUNDING

HPTN/NIAD/NIH

KEY OBJECTIVE

DURATIONS

2005 - 2015

PUBLICATIONS

Randomized Control Trial of Structured Interrupted Generic Antiretroviral Therapy (SIT) versus Continuous Therapy (CT) in HIV-infected Individuals

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy, Dr.Timothy Flanigan,Dr.Kenneth Mayer

COLLABORATORS

Brown University

FUNDING

Fogarty/Brown University/NIH

KEY OBJECTIVE

DURATIONS

2003-2004

PUBLICATIONS

N.Kumarasamy, Timothy P. Flanigan, Snigdha Vallabhaneni et al. A randomised control trial of structured interrupted generic antiretroviral therapy versus continuous therapy in HIV-infected individuals in Southern India. AIDS Care. 2007 Apr;19(4):507-13. PMID: 17453591

Prevalence and Incidence of Sexually Transmitted Infections among South Indians at Increased Risk of HIV Infection

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy, Dr.Kenneth Mayer

COLLABORATORS

Brown University

FUNDING

Fogarty/Brown University/NIH

KEY OBJECTIVE

DURATIONS

2002- 2003

Correlates of ART Adherence in Chennai

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy, Dr.Steve Safren

COLLABORATORS

Fenway Centre,Boston;Brown University,RI

FUNDING

Fogarty/Brown University, RI, USA

KEY OBJECTIVE

DURATIONS

2002-2003

PUBLICATIONS

GSK TB 014 Project – A Phase II, Double Blind (Observer-Blind), Randomised, Controlled Study To Evaluate The Safety, Reactogenicity And Immunogenicity of GSK Biologicals’ Candidate Tuberculosis Vaccine (M72/As01e) When Administered Intramuscularly According To A 0,1 Month Schedule To HIV-Positive Adults Living In A TB Endemic Region

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

GSK R&D

FUNDING

GSK

KEY OBJECTIVE

DURATIONS

2011 – 2015

PUBLICATIONS

Kumarasamy N, Poongulali S, Bollaerts A et al. A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults. Medicine (Baltimore). 2016 Jan;95(3):e2459. PMID: 26817879

AMC #054 – A Single-Arm, Open-Label Pilot Study of the Safety and Immuno genicity of the Merck Quadrivalent Human Papillomavirus Vaccine among HIV-Positive Women in India: A Trial of the AIDS Malignancy: Clinical Trials Consortium (AMC).

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy, Dr.Joel Palefsky

COLLABORATORS

UCSF,CA,USA

FUNDING

AMC/NCI

KEY OBJECTIVE

DURATIONS

2009 - 2011

PUBLICATIONS

Joel Palefsky, Selvamuthu Poongulali, Shelly Lensing et al. AMC 054: Safety and Immunogenicity of the Quadrivalent HPV Vaccine in Indian HIV-Infected Women. CROI 2014.Abs.No:855

SECONDLINE STUDY- A Randomised Open-Label Study comparing the Safety and Efficacy of Ritonavir boosted Lopinavir and 2-3N(T)RTI Backbone versus Ritonavir boosted Lopinavir and Raltegravir in Participants Virologically Failing First-Line NNRTI/2N(T)RTI Therapy

HIVIND – The Antiretroviral Roll out for HIV in India – Strengthening Capacity to Promote Adherence and Patient follow-up in the Context: A Research Plan for a Two-Centre, Randomized, Controlled, Open Trial in South India to Study an Innovative approach to Promote Adherence in HIV + Indian Patients

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy, Dr.Anita Shet, Dr.Vinod Diwan

COLLABORATORS

Karolinsk Institute,Sweden; St.Johns Medical College, Bangalore

FUNDING

EU/ Karolinka Institute,Sweden

KEY OBJECTIVE

DURATIONS

2010 - 2013

WRHI001-GATES- A Randomized, Double-Blind, Multi-Centre, Parallel-Group Phase 3b Study To Demonstrate Non-Inferiority Of Stavudine (20 Mg Twice Daily) Compared With Tenofovir Disoproxil Fumarate (300 Mg Once Daily) When Administered In Combination With Lamivudine And Efavirenz In Anti Retroviral-Naive Patients Infected With HIV-1

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

Dr.Francois Venter,WITS,Johannesburgh; Dr.Andrew Kambugu,IDI,Kampala

FUNDING

Gates Foundation

KEY OBJECTIVE

DURATIONS

2012 - 2015

PUBLICATIONS

Manuscripts in preparation

K23- Impact of Malaria Co-Infection on HIV-Associated Neurocognitive Disorders

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy, Dr.Ajay Bharti

COLLABORATORS

UCSD,CA,USA

FUNDING

CFAR/UCSD/NIH

KEY OBJECTIVE

DURATIONS

2012 - 2013

PUBLICATIONS

Bharti A, Saravanan S, Madhavan V et al. Correlates of HIV and malaria co-infection in Southern India. Malar J. 2012 Sep 3;11:306. PMID: 22943054

REACH TIBOTECH:Malaria and HIV Co-infection in Southern India

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy, Dr.Ajay Bharti

COLLABORATORS

UCSD,CA,USA

FUNDING

Tibotech

KEY OBJECTIVE

DURATIONS

2010 - 2012

PUBLICATIONS

Under review

GIVCYT- Ganciclovir—Intravitreous Versus Systemic—Cytomegalovirus Retinitis Trial

PRINCIPAL INVESTIGATORS

Dr.Jyotirmay Biswas, Dr.John Kempen, Dr.N.Kumarasamy, Dr. Sudharsan, Dr.S.Poongulali

COLLABORATORS

Sankara Nethralaya

FUNDING

National Eye Institute (NEI)- NIH

KEY OBJECTIVE

To determine whether systemic therapy or IV Gancyclovir treatment is superior vis-à-vis the outcomes of mortality and retinitis progression for treatment of CMV retinitis among patients with AIDS in locations where IV Gancyclovir is standard of care.

DURATIONS

2011-2013

PUBLICATIONS

Nil.

UNITE: A Randomized, Controlled Trial To Assess The Impact Of TAMA (Health It System) On Treatment Effectiveness InHIV-1Infected Subjects Initiated On First-Line Antiretroviral Therapy

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy, Dr.Anirudha Joshi

COLLABORATORS

Dr.Sanjay Pujari, IIT Design Dept, Johnson & Johnson IT Dept

FUNDING

Janssen

KEY OBJECTIVE

DURATIONS

2014 - 2015

PUBLICATIONS

  • Anirudha Joshi, Mandar Rane, Debjani Roy et al.
Supporting treatment of people living with HIV/AIDS in resource limited settings with IVRs. Proceedings of the SIGCHI Conference on Human Factors in Computing Systems: 2014/4/26. Pages: 1595-1604.
  • A Joshi, M Rane, D Roy et al.
Human-Computer Interaction Design opportunities for supporting treatment of people living with HIV/AIDS in India. INTERACT 2011, 315-332

HIV Tropism study – A Multicenter, Cross-sectional Survey of HIV-1 Viral Co-receptor Tropism in Patients infected with Clade C HIV-1 at select sites in India

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

Pfizer

FUNDING

Pfizer

KEY OBJECTIVE

DURATIONS

2008

PUBLICATIONS

Study group. The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections fromIndia, Uganda and South Africa. J Int AIDS Soc. 2012 Jan 26;15(1):2.

A4001050- A Multi-Centre, Open Label, Expanded Access Trial of Maraviroc

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

Pfizer

FUNDING

Pfizer

KEY OBJECTIVE

DURATIONS

2008 - 2010

PUBLICATIONS

Nil

A0082144 –Randomized,, Double –Blind ,Placebo-controlled, parallel group ,Multicenter Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated with HIV Neuropathy. Pregabalin A0081251- Phase 3B – An Open-Label, extension safety trial of Pregabalin in subjects with Neuropathic Pain associated with HIV Neuropathy

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

Pfizer

FUNDING

Pfizer

KEY OBJECTIVE

DURATIONS

2011 - 2012

PUBLICATIONS

ARIEL/TMC 114-TIDP29-C228-A Phase II, Open-Label Trial to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral activity of DRV in combination with Low Dose Ritonavir(DRV/RTV) in Treatment-experienced HIV-1 Infected Children from 3 Years to <6 Years of age

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

Tibotec

FUNDING

Tibotec

KEY OBJECTIVE

DURATIONS

2009-2010

PUBLICATIONS

Violari A, Bologna R, Kumarasamy N et. Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial. Pediatr Infect Dis J. 2015 May;34(5):e132-7. PMID: 25719453

TMC278-TiDP6-C215 – A Phase III, Randomized, Double-blind Trial Of TMC278 25 mg q.d. Versus Efavirenz 600 mg q.d. In Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors In Antiretroviral-Naive HIV-I Infected Subjects

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

Tibotec

FUNDING

Tibotec

KEY OBJECTIVE

DURATIONS

2008-2012

ACH443-015 Achillion: A Phase II, Randomized, Blinded, 12-Week Comparison of Elvucitabine in Combination with Efavirenz and Tenofovir Versus Lamivudine in Combination with Efavirenz and Tenofovir in HIV-1 infected, Treatment-naïve Subjects, with an 84-Week Extension Treatment Period

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy

COLLABORATORS

Achillion

FUNDING

Achillion

KEY OBJECTIVE

DURATIONS

2007 - 2009

PUBLICATIONS

Study Group, Phase 2, 48 Weeks data on Antiviral Activity and Safety Profile of Elvucitabine. Abstract: XVII International AIDS Conference in Mexico City on August 5, 2008.

Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy, Dr.Tom Nutman

COLLABORATORS

Dr.Sowmya Swaminathan,NIRT,Chennai; Dr. Kawser,LIP/NIAID/NIH

FUNDING

NIAID/NIH

KEY OBJECTIVE

DURATIONS

2007 - 2011

PUBLICATIONS

HIV resistance in India-HIV Drug Resistance in Blood and Genital Tract in India, Version 1.0, Version dated April 28, 2007

PRINCIPAL INVESTIGATORS

Dr.N. Kumarasamy,Dr.Saravanan, Dr.Rami Kantor& Dr. Charles Carpenter

COLLABORATORS

Brown University

FUNDING

CFAR/Brown University

KEY OBJECTIVE

DURATIONS

2009 - 2011

PUBLICATIONS

Presented at IAS 2014, Melbourne. (give the citation)

Detection of Herpes viruses in Oral Fluids from HIV Positive patients in Chennai, India

PRINCIPAL INVESTIGATORS

Dr.Ranganathan, Prof Newell W Johnson, Mr. David Speicher, Dr.Kumarasamy

COLLABORATORS

Ragas Dental College,Griffith University,Australia

FUNDING

Griffith University,Australia Australia

KEY OBJECTIVE

DURATIONS

2011 - 2013

PUBLICATIONS

Presented at WW7, 2014,Hyderabad

Impact of Alcohol on HIV transmission and ART adherence

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy, AK Srikrishnan,Dr.Maria Ekstrand

COLLABORATORS

UCSF

FUNDING

NIAAA/NIH

KEY OBJECTIVE

DURATIONS

PUBLICATIONS

Rodríguez DC, Krishnan AK, N.Kumarasamy  et al. Two sides of the same story: alcohol use and HIV risk taking in South India. AIDS Behav. 2010 Aug;14 Suppl 1:S136-46. PMID: 20544382

Immue Activation in Vrologically Suppressed persons with HIV who are on ART

PRINCIPAL INVESTIGATORS

Dr.N.Kumarasamy, Dr.Murugavel, Dr.Savita Pahwa

COLLABORATORS

University of Miami,Florida,USA

FUNDING

ICMR/NIH

KEY OBJECTIVE

DURATIONS

2014 - 2015

PUBLICATIONS

Analysis ongoing.

Anemia and Nutrition among Children with Perinatally Acquired HIV Infection in South India

PRINCIPAL INVESTIGATORS

Dr.Poongulali,Dr.Anita Shet,Dr.N.Kumarasamy

COLLABORATORS

St.Johns,Banagalore; Dr.Sowmya Swaminathan, NIRT,Chennai

FUNDING

ICMR

KEY OBJECTIVE

DURATIONS

2010 - 2012

PUBLICATIONS

Shet A, Bhavani PK, Kumarasamy N et al. Anemia, diet and therapeutic iron among children living with HIV: a prospective cohort study. BMC Pediatr. 2015 Oct 19;15:164. PMID: 26482352

HPV-019 PRI – A Phase IV, Observer-Blind, Randomized, Controlled, Multi centric Study to Assess the Safety and Immunogenicity of GSK Biologicals’ HPV -16/18 L1 VLP AS04 Vaccine (Cervarix) Administered Intramuscularly According to A 3-Dose Schedule (Month 0, Week 6, Month 6) in Human Immunodeficiency Virus-Infected (HIV +) Female Subjects Aged 15-25 Years, as Compared to Merck’s HVP 6/11/16/18 Vaccine (Gardasil)

PRINCIPAL INVESTIGATORS

Dr.S.Poongulali,Dr.N.Kumarasamy,

COLLABORATORS

GSK R&D

FUNDING

GSK

KEY OBJECTIVE

DURATIONS

2010 - 2013

PUBLICATIONS

available separate file

HAART associated body composition and metabolic changes in HIV infected patients in South India

PRINCIPAL INVESTIGATORS

Dr.Suneetha Sagayam,

COLLABORATORS

Dr.Kumarasamy; Dr. Kenneth Mayer, Brown University;, Dr. Christine Wanke, Tufts University,USA

FUNDING

GRIP/Fogarty/Brown-Tufts Univ/NIH

KEY OBJECTIVE

DURATIONS

2007 - 2013

PUBLICATIONS

Neurocognitive Impairment in HIV

PRINCIPAL INVESTIGATORS

Dr.Tokugha Yepthomi

COLLABORATORS

Brown University,RI,USA

FUNDING

Fogarty Program/Brown University

KEY OBJECTIVE

DURATIONS

2002-2003

PUBLICATIONS

Yepthomi T, Paul R, Vallabhaneni S et al. Neurocognitive consequences of HIV in southern India: a preliminary study of clade C virus. J Int Neuropsychol Soc. 2006 May;12(3):424-30. PMID: 16903135

HPV Co-infection among HIV positive women in Chennai: A Pilot study

PRINCIPAL INVESTIGATORS

Dr.Poongulali Selvamuthu, Dr.Lyn Menezes, Dr.N.Kumarasamy

COLLABORATORS

USF

FUNDING

USF

KEY OBJECTIVE

DURATIONS

2011

PUBLICATIONS

Menezes LJ, Poongulali S, Tommasino M et al. Prevalence and concordance of human papillomavirus infection at multiple anatomic sites among HIV-infected women from Chennai, India. Int J STD AIDS. 2016 Jun;27(7):543-53. PMID: 26002318

A longitudinal study on HAART associated body composition, metabolic and quality of life changes

PRINCIPAL INVESTIGATORS

Dr.Suneetha Sagayam

COLLABORATORS

Dr.Kumarasamy; Dr. Kenneth Mayer, Brown University;Dr. Christine Wanke, Tufts University,USA

FUNDING

Fogarty/Brown-Tufts Univ/NIH

KEY OBJECTIVE

DURATIONS

2003-2005

PUBLICATIONS

available separate file